Año:
2015
CiteScore:
55,200
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| General Medicine | 11/3276 | Q1 | T1 | D1 |
SJR año:
2015
Factor de Impacto:
14,974
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Medicine (miscellaneous) | 7/2816 | Q1 | T1 | D1 |
| Medicine (miscellaneous) | 7/2830 | Q1 | T1 | D1 |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Griffiths C.E.M. | The University of Manchester (United Kingdom) |
| 2 | Reich K. | Dermatologikum Hamburg and SCIderm Research Institute (Germany) |
| 3 | Lebwohl M. | Icahn School of Medicine at Mount Sinai (United States) |
| 4 | Van De Kerkhof P. | Radboud Universiteit (Netherlands) |
| 5 | Paul C. | Université Toulouse III - Paul Sabatier (France) |
| 6 | Menter A. | UT Southwestern Medical School (United States) |
| 7 | Cameron G.S. | Eli Lilly and Company (United States) |
| 8 | Erickson J. | Eli Lilly and Company (United States) |
| 9 | Zhang L. | Eli Lilly and Company (United States) |
| 10 | Secrest R.J. | Eli Lilly and Company (United States) |
| 11 | Ball S. | Eli Lilly and Company (United States) |
| 12 | Braun D.K. | Eli Lilly and Company (United States) |
| 13 | Osuntokun O.O. | Eli Lilly and Company (United States) |
| 14 | Heffernan M.P. | Eli Lilly and Company (United States) |
| 15 | Nickoloff B.J. | Eli Lilly and Company (United States) |
| 16 | Papp K. | Probity Medical Research (Canada) |
| # | Autoría grupal | Afiliación |
| 1 | UNCOVER-2 | Sin datos () |
| 2 | UNCOVER-3 investigators | Sin datos () |
| 3 | Ferrandiz Pulido, Lara (UNCOVER-2) | Sin datos () |
